Research analysts at StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 1-year low of $0.00 and a 1-year high of $0.00.
About Genocea Biosciences
Read More
- Five stocks we like better than Genocea Biosciences
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Occidental Stock: Buffett’s 9-Day Buying Spree Lifts Stake to 29%
- What is a Death Cross in Stocks?
- 3M Stock: Invest Now for Unmatched Quality and Growth Potential
- How to Calculate Options Profits
- Super Micro AI Stock: Should You Invest After a 275% Increase?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.